z-logo
Premium
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second‐line Helicobacter pylori eradication in Japan , and the influence of metronidazole resistance
Author(s) -
Murakami K.,
Sato R.,
Okimoto T.,
Nasu M.,
Fujioka T.,
Kodama M.,
Kagawa J.
Publication year - 2003
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2003.01401.x
Subject(s) - metronidazole , amoxicillin , rabeprazole , helicobacter pylori , clarithromycin , medicine , gastroenterology , antibiotics , drug resistance , proton pump inhibitor , microbiology and biotechnology , pharmacology , biology
Summary Background : The widespread use of eradication therapy for Helicobacter pylori in Japan has led to an increase in antibiotic‐resistant strains and the problem of re‐treatment in cases of eradication failure. Aim : To perform drug sensitivity testing for metronidazole in 92 H. pylori ‐positive patients who had failed eradication treatment with first‐line triple therapy, consisting of a proton pump inhibitor, amoxicillin and clarithromycin, and were administered metronidazole‐containing second‐line therapy. Methods : Second‐line eradication therapy, consisting of rabeprazole (20 mg b.d.), amoxicillin (750 mg b.d.) and metronidazole (250 mg b.d.), was administered for 1 week and the eradication rates and influence of metronidazole resistance were determined. Results : The eradication rates for rabeprazole–amoxicillin–metronidazole were 88% (81/92) using intention‐to‐treat analysis and 91% (81/89) using per protocol analysis. The eradication rates were 97% (61/63) for metronidazole‐sensitive strains and 82% (18/22) for metronidazole‐resistant strains. Conclusions : As second‐line H. pylori eradication treatment in Japan, rabeprazole–amoxicillin–metronidazole triple therapy is effective, even with metronidazole‐resistant strains.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here